Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822404 | 0.77 | PDCD1 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL9566297 | 0.77 | IDO1 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4821504 | 0.77 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1564661 | 0.77 | HTT (0.44) | HTT | |
| SCHEMBL875044 | 0.77 | BACE1 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL27610986 | 0.76 | IDO1 (0.51) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3090308 | 0.75 | SMYD2 (0.33) | SMYD2FFAR1 | |
| SCHEMBL31245516 | 0.74 | HTT (0.37) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL10349815 | 0.74 | HTT (0.37) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL2473646 | 0.74 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541626-B2 | Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | claimed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-111556872-B | Synthesis of borate derivatives and uses thereof | 梅琳塔治疗公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11237156-B2 | Method and composition for detection of peptide cyclization using protein tags | Roche Sequencing Solutions, Inc. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-107835871-B | Methods and compositions for peptide cyclization and protease treatment | 豪夫迈·罗氏有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20030044831-A1 | Antibody for use in the generation and protection of preferential nucleotide sequences | AGRIS PAUL F (US) | 2003-03-06 | — | — | US | disclosed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | disclosed |
| WO-2003003014-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF AND PURIFYING CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI-Q, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1242459-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020045167-A1 | Used for detecting incomplete deprotection of a synthetic oligonucleotide by immunoassay | VERI-Q, INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001049745-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | UNIV NORTH CAROLINA STATE (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001049745-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | SMYD2 3309/4885CYP3A4 43/4885HTT 4861/4885 |
| US-20030044831-A1 | Antibody for use in the generation and protection of preferential nucleotide sequences | CD2BP2, IGSF11, RNGTT | SMYD2 2834/4885CYP3A4 4805/4885HTT 2509/4885 |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | PNP, NUDT1, ADAR | SMYD2 2009/4885CYP3A4 2872/4885HTT 2416/4885 |
| US-11237156-B2 | Method and composition for detection of peptide cyclization using protein tags | CACYBP, VIP, PTMS | SMYD2 3334/4885CYP3A4 4390/4885HTT 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.